Inflectra® is indicated for the treatment of severe, active CD, and severely active UC, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy‡; or who are intolerant to or have contraindications for such therapies2.

Studies in Crohn's Disease (CD) and Ulcerative Colitis (UC)46,47


 

Clinical efficacy46,47 – as well as improvements across a range of objective measures such as CRP and FC46 – have been demonstrated in 5 real-world paediatric studies.

Real World Evidence in IBD
 

Study Results 

Results across these studies support the use of Inflectra®/CTP-13* (infliximab) in paediatric patients with CD and UC61-63.

Study Results Across Paediatric Patients with CD and UC
 

Click below to read more about Inflectra® evidence in IBD:

Induction and Maintenance

Switch Studies

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

‡ In CD: corticosteroid, immunomodulator and primary nutrition therapy; in UC: corticosteroid and 6-mercaptopurine or azathloprine46.
*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA® .

ADA, Antidrug antibody; AE, Adverse event; ATI, Antibodies to infliximab; CD, Crohn’s disease; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; FC, Fecal calprotectin; HBI, Harvey-Bradshaw Index; IBD, Inflammatory bowel disease; SAE, Serious adverse event; SCCAI, Simple Clinical Colitis Activity Index; TEAE; Treatment-emergent adverse event; TESAE. Treatment-emergent serious adverse event; TL, Trough level; UC, Ulcerative colitis.

 

PP-IFA-GBR-0309. December 2018